Market trend and competition pattern of over repeated catalogue of 1 billion + varieties

Source: on September 14, 2016, CFDA issued 282 notices of over repeated drug prompt information Statistics show that 10 enterprises of the same product can basically meet the market demand CFDA reminds relevant pharmaceutical manufacturers and R & D institutions to fully understand the supply and demand of the market, scientifically assess the risk of drug R & D, and prudently make investment and operation decisions It is divided into three camps The 282 over repeated drugs released this time involve 13 categories, which can be divided into three camps In the first camp, there are more than 60 varieties, including systemic anti infective drugs, digestive system and metabolic drugs; in the second camp, there are 5 fields between 20 and 40 varieties; in the third camp, there are 6 fields below 10 varieties The first camp: there are two over 60 products: systemic anti infective drugs (63), digestive system and metabolic drugs (61) The second camp: there are 5 areas between 20 and 40: cardiovascular system drugs (33), blood and hematopoietic system drugs (28), nervous system drugs (26), respiratory system drugs (23), dermatology drugs (22) Third camp: there are 6 products in the following 10 areas: muscle bone system (7), genitourinary system and sex hormone drugs (6), miscellaneous drugs (5), sensory system drugs (3), antitumor and immunomodulator (3), systemic hormone drugs (2) 282 over repeated varieties involve comparison of large categories The sales volume of sample hospitals is more than 1 billion yuan 1 Sales volume of sodium chloride: 1.95 billion yuan Number of enterprises: 114 top 10 enterprises, accounting for 71.1% of sales volume 2005-2015 Market situation of domestic sample hospitals of sodium chloride and market pattern in 2015 sodium chloride injection belongs to intravenous infusion and electrolyte supplement, which can supplement blood volume and sodium ion, and plays an important role in the treatment of severe and emergency In 2015, sodium chloride accounted for 11.5% of the blood and hematopoiesis categories Sodium chloride injection has also been listed in 2004 and 2009 edition of the national medical insurance catalog class a drugs According to the monitoring data of sample hospitals in key cities in 2015, the amount of sodium chloride injection has reached 1.95 billion yuan, an increase of 2.5% over the same period last year From the perspective of sales trend in 2005-2015, the growth of sodium chloride injection in 2005-2014 was strong, but the market growth slowed down since 2015 There are 114 enterprises involved in sodium chloride infusion, with sales volume of 1.95 billion yuan in 2015 The top 10 enterprises account for 71.1% of the total sales volume, and other enterprises account for 28.9% Among them, the top five enterprises are: Sichuan Kelun pharmaceutical sales volume is 290 million yuan, accounting for 15.0%; Shanghai Baite sales volume is 200 million yuan, accounting for 10.0%; China Otsuka pharmaceutical sales volume is 190 million yuan, accounting for 9.8%; Huaren pharmaceutical sales volume is 180 million yuan, accounting for 9.0%; Shijiazhuang No.4 pharmaceutical sales volume is 170 million yuan, accounting for 8.6% The top 5 products accounted for 52.6% 2 Paclitaxel sales: 1.48 billion yuan, number of enterprises: 30 top 10 enterprises sales proportion: 96.0% market situation of paclitaxel domestic sample hospitals in 2005-2015 and market pattern in 2015 paclitaxel is mainly used in ovarian cancer, breast cancer and NSCLC First and second line treatment The original research drug of paclitaxel was approved by FDA in 1992, and it was first imitated and listed by Haikou pharmaceutical factory in 1998 in China Since then, several imitated varieties have been listed successively At present, the products of 30 enterprises have been sold on the market According to the monitoring data of sample hospitals in key cities in 2015, the amount of paclitaxel used has reached 1.48 billion yuan, an increase of 6.9% over the same period last year, and the growth rate has been relatively fast from 2005 to 2015 There are 30 enterprises involved in paclitaxel In 2015, the sales volume was 1.48 billion yuan, and the top 10 sales accounted for 96.0% of the total sales volume Among them, the top three enterprises are Nanjing LVYE Cisco Pharmaceutical Co., Ltd with sales volume of 860 million yuan, accounting for 58.1%; BMS (Bristol Myers Squibb) with sales volume of 210 million yuan, accounting for 14.4%; abraxis with sales volume of 110 million yuan, accounting for 7.7% The products of the top three enterprises account for 80.2% in total The most outstanding performance is the Lipitor liposome of paclitaxel for injection, which was developed and launched by Nanjing LVYE Cisco in 2003 It is the largest brand product in the domestic paclitaxel market 3 Sales of lansoprazole: 1.35 billion yuan; number of enterprises: 36 top 10 enterprises; sales proportion: 95.2%; market situation of lansoprazole domestic sample hospitals in 2005-2015 and market pattern in 2015 Lansoprazole is the second generation proton pump inhibitor, which is mainly used in gastric ulcer, duodenal ulcer and reflux esophagitis The dosage forms are powder injection, tablet and capsule According to the monitoring data of sample hospitals in key cities in China in 2015, the amount of lansoprazole has reached 1 billion 350 million yuan, an increase of 0.6% compared with the same period last year From the perspective of sales trend in 2005-2015, lansoprazole experienced three stages: the development was relatively slow in 2005-2009; the growth was rapid in 2010-2014; and the sales slowed down in 2015 It is worth noting that lansoprazole has greatly promoted the rapid growth of market share after entering the national health insurance catalog in 2009 There are 36 enterprises involved in Lansoprazole In 2015, the sales volume was 1.35 billion yuan, and the top 10 enterprises accounted for 95.2% of the total sales volume The top five enterprises are Jiangsu aosaikang Pharmaceutical Co., Ltd with sales volume of 500 million yuan, accounting for 36.8%; Shandong Luoxin Pharmaceutical Co., Ltd with sales volume of 330 million yuan, accounting for 24.2%; Beijing yuekang Pharmaceutical Co., Ltd with sales volume of 170 million yuan, accounting for 12.4%; Changzhou No.4 Pharmaceutical Co., Ltd with sales volume of 110 million yuan, accounting for 8.2%; Tianjin Wutian Pharmaceutical Co., Ltd with sales volume of 54.29 million yuan, accounting for 4.0% The top five enterprises account for 85.6% of the market share, while the top four are all local enterprises Among them, Jiangsu aosaikang occupies nearly 4 ingredients, ranking first for many years 4 Pantoprazole sales: 1.23 billion yuan; number of enterprises: 62 top 10 enterprises; sales proportion: 83.0%; market situation of pantoprazole domestic sample hospitals in 2005-2015 and market pattern in 2015 Pantoprazole is the third generation proton pump inhibitor, which is mainly used in active peptic ulcer (gastric and duodenal ulcer), reflux esophagitis and Zhuo AI syndrome The dosage forms are powder injection, tablet and capsule Pantoprazole was first listed by Dongyu Pharmaceutical Co., Ltd in Shenyang, Liaoning Province in 1999, with the trade name of "temenk" According to the monitoring data of sample hospitals in key cities in 2015, the amount of pantoprazole used reached 1.23 billion yuan, an increase of 13.0% over the same period last year From 2005 to 2015, the market has maintained a sustained growth trend Pantoprazole involves 62 enterprises, with sales of 1.23 billion yuan in 2015, and the top 10 enterprises account for 83.0% of the total sales The top five enterprises are: Nycomed sales volume is 320 million yuan, accounting for 26.1%; Hangzhou, China, the United States and East China pharmaceutical sales volume is 240 million yuan, accounting for 19.4%; Yangtze River Pharmaceutical sales volume is 180 million yuan, accounting for 14.3%; BYK gulden lomberg Chemische fabric GmbH sales volume is 95.76 million yuan, accounting for 7.8%; Hainan Weikang Pharmaceutical (Qianshan) sales volume is 7191 RMB 10000, accounting for 5.8% The top five products account for 73.3% of the market share The products are dominated by foreign enterprises, and the local enterprises Jiangsu Yangzijiang Pharmaceutical Co., Ltd and Hainan Weikang Pharmaceutical Co., Ltd have entered the top 5 5 Sales of thymopentin: 1.21 billion yuan; number of enterprises: 22 top 10 enterprises; sales proportion: 99.4%; market situation of domestic sample hospitals in 2005-2015 and market pattern in 2015 Thymopentin is a two-way modulator of immune function, which is widely used in clinic In 1997, the thymopentin developed by Hainan Zhonghe Pharmaceutical Co., Ltd took the lead in listing in China, with the trade name of "Hexin" According to the monitoring data of sample hospitals in domestic key cities in 2015, the amount of thymopentin used reached 1.21 billion yuan, down 8.1% year on year From the perspective of sales trend in 2005-2015, 2005-2014 has maintained a rapid growth rate, and the market has declined in 2015 There are 22 enterprises involved in thymopentin, with sales volume of 1.21 billion yuan in 2015 The top 10 enterprises account for 99.4% of the total sales volume Among them, the top five enterprises are Hainan Zhonghe Pharmaceutical Co., Ltd with sales of 257 million yuan, accounting for 21.3%; Beijing Shiqiao bio Pharmaceutical Co., Ltd with sales of 254 million yuan, accounting for 21.0%; Wuhan Hualong bio Pharmaceutical Co., Ltd with sales of 186 million yuan, accounting for 15.3%; Shenzhen Hanyu Pharmaceutical Co., Ltd with sales of 185 million yuan, accounting for 15.3%; Beijing Shuanglu Pharmaceutical Co., Ltd with sales of 184 million yuan, accounting for 15.2% The products of top 5 enterprises account for 88.1%, and all of them are local enterprises